TW212796B - - Google Patents

Download PDF

Info

Publication number
TW212796B
TW212796B TW081109961A TW81109961A TW212796B TW 212796 B TW212796 B TW 212796B TW 081109961 A TW081109961 A TW 081109961A TW 81109961 A TW81109961 A TW 81109961A TW 212796 B TW212796 B TW 212796B
Authority
TW
Taiwan
Prior art keywords
group
acid
page
standards
formula
Prior art date
Application number
TW081109961A
Other languages
English (en)
Chinese (zh)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of TW212796B publication Critical patent/TW212796B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
TW081109961A 1992-01-13 1992-12-12 TW212796B (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929200623A GB9200623D0 (en) 1992-01-13 1992-01-13 Benzofuranyl and thiophenyl-methylthio-alkanecarboxylic acid derivatives

Publications (1)

Publication Number Publication Date
TW212796B true TW212796B (enExample) 1993-09-11

Family

ID=10708497

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081109961A TW212796B (enExample) 1992-01-13 1992-12-12

Country Status (13)

Country Link
EP (1) EP0551662A1 (enExample)
JP (1) JPH05271214A (enExample)
KR (1) KR930016413A (enExample)
CN (1) CN1074904A (enExample)
AU (1) AU3108293A (enExample)
CA (1) CA2086987A1 (enExample)
GB (1) GB9200623D0 (enExample)
HU (1) HUT64952A (enExample)
IL (1) IL104356A0 (enExample)
MX (1) MX9207557A (enExample)
PL (1) PL297337A1 (enExample)
TW (1) TW212796B (enExample)
ZA (1) ZA93190B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP950288A2 (en) * 1994-05-31 1997-08-31 Bayer Ag Oxalylamino-benzofuran- and benzothienyl-derivatives
GB9410877D0 (en) * 1994-05-31 1994-07-20 Bayer Ag Heterocyclycarbonyl substituted benzoduranyl-and-thiophenyl-alkanecarboxyclic acid derivatives
ES2127966T3 (es) * 1994-05-31 1999-05-01 Bayer Ag Derivados de amino-benzofurilo y -benzotienilo.
GB9504460D0 (en) * 1995-03-06 1995-04-26 Bayer Ag N-(3-Benzofuranyl)urea-derivatives
US5763496A (en) * 1995-11-27 1998-06-09 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
GB9614718D0 (en) 1996-07-12 1996-09-04 Bayer Ag 3-ureido-pyridofurans and -pyridothiophenes
US5908859A (en) * 1997-08-11 1999-06-01 Eli Lilly And Company Benzothiophenes for inhibiting hyperlipidemia
US6090851A (en) * 1997-09-10 2000-07-18 Johns Hopkins University School Of Medicine Use of an NADPH-oxidase inhibitor in the treatment of reperfusion injury
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
AU2003215380B2 (en) 2002-02-22 2008-10-02 Bayer Pharmaceuticals Corporation Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
US7144885B2 (en) 2002-02-22 2006-12-05 Bayer Pharmaceuticals Corporation Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
WO2003087399A1 (en) 2002-04-17 2003-10-23 Glucox Ab Nad)p)h oxidase inhibitors for increased glucose uptake and treatment of type ii diabetes
AU2003252140A1 (en) * 2002-07-24 2004-02-09 Janssen Pharmaceutica N.V. Acetylenic compounds useful in treating inflammatory disorders
US7022703B2 (en) 2003-07-24 2006-04-04 Janssen Pharmaceutica, N.V. Acetylenic compound useful in treating inflammatory disorders
US7119214B2 (en) * 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
CN102267990B (zh) * 2011-06-03 2013-11-13 浙江工业大学 一种2,3-二氢苯并呋喃类衍生物及其制备与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146243A1 (en) * 1983-10-31 1985-06-26 Merck Frosst Canada Inc. Lipoxygenase inhibitors
JP2855341B2 (ja) * 1988-06-10 1999-02-10 武田薬品工業株式会社 新規2―置換クマラン誘導体

Also Published As

Publication number Publication date
CN1074904A (zh) 1993-08-04
AU3108293A (en) 1993-07-15
MX9207557A (es) 1993-07-01
ZA93190B (en) 1993-08-13
EP0551662A1 (en) 1993-07-21
HU9300078D0 (en) 1993-04-28
HUT64952A (en) 1994-03-28
GB9200623D0 (en) 1992-03-11
IL104356A0 (en) 1993-05-13
CA2086987A1 (en) 1993-07-14
PL297337A1 (en) 1994-01-24
KR930016413A (ko) 1993-08-26
JPH05271214A (ja) 1993-10-19

Similar Documents

Publication Publication Date Title
US9409865B2 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
JP5897566B2 (ja) 環式n,n’−ジアリールチオ尿素及びn,n’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用
US20230286904A1 (en) Inhibitors of yap/taz-tead oncoproteins, synthesis and use thereof
JP2002514644A (ja) メタロプロテイナーゼ阻害剤としての置換アリールヒドロキサム酸
WO2009055721A2 (en) 5-lipoxygenase activating protein (flap) inhibitor
US20250074904A1 (en) Nsd2-targeted checmical degraderts and compositions and methods of use thereof
NO313912B1 (no) Guanidinylheterocykelforbindelser anvendelige som <alfa>-2 adrenoceptoragonister
US5804587A (en) 6-(2-imidazolinylamino) quinolines useful as alpha-2 adrenoceptor agonists
US5916900A (en) 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
CN114409638B (zh) 组蛋白去乙酰化酶8选择性降解剂、制备方法及其在抗肿瘤活性中的应用
US20260103470A1 (en) Androgen receptor regulation by small molecule enantiomers
US6110952A (en) 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists
CN101704792B (zh) 具有基质金属蛋白酶抑制活性的喹喔啉酮类衍生物及其制备方法和应用
US5914342A (en) 2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists
TW200924765A (en) Piperidine derivative
TW201302736A (zh) 組織蛋白酶(Cathepsin)C抑制劑
US20260085036A1 (en) Novel nootropic prodrugs of henethylamine
WO2010040315A1 (zh) 1-丁基-2-羟基芳烷哌嗪衍生物及作为抗抑郁剂的应用
CN107365301B (zh) 一种克唑替尼的合成方法及其中间体制备方法
EP3677581A1 (en) Deuterated indoleamine 2,3-dioxygenase inhibitor and application thereof
WO2020156571A1 (zh) 一种哒嗪衍生物及其制备方法和医药用途
US20250376477A1 (en) Analgesic delta opioid receptor bitopic ligands
EP2185525B1 (fr) Dérivés de pyrazole 3,5-carboxylates, leur préparation et leur application en thérapeutique
WO2001000588A1 (en) Benzimidazole compounds and drugs containing the same
WO1998023609A1 (en) 2-imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonists